Literature DB >> 9152836

Homozygosity by descent for a rare mutation in the myophosphorylase gene is associated with variable phenotypes in a Druze family with McArdle disease.

S Iyengar1, H Kalinsky, S Weiss, M Korostishevsky, M Sadeh, Y Zhao, K K Kidd, B Bonne-Tamir.   

Abstract

We examined a large consanguineous Druze family with McArdle disease for mutations in the glycogen myophosphorylase (PYGM) gene. All affected subjects were autozygous for a single G to A transition that abolishes the 5' consensus splice site in the first nucleotide of intron 14. The G to A transition is a rare mutation, with only one previous report in a single white subject heterozygous for this mutation and another, more common, mutation at codon 49. The kindred in our study is the first family reported in which disease is caused by homozygosity for this rare mutation. This kindred was originally reported as the first familial case of McArdle disease in the Druze.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152836      PMCID: PMC1050946          DOI: 10.1136/jmg.34.5.391

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

1.  A minisatellite and a microsatellite polymorphism within 1.5 kb at the human muscle glycogen phosphorylase (PYGM) locus can be amplified by PCR and have combined informativeness of PIC 0.95.

Authors:  H Iwasaki; P W Stewart; W G Dilley; M S Holt; T D Steinbrueck; S A Wells; H Donis-Keller
Journal:  Genomics       Date:  1992-05       Impact factor: 5.736

2.  Regional localization of the highly polymorphic locus D11S533 on the linkage map of human chromosome 11q.

Authors:  M Litt; J H Eubanks; G A Evans; T Phromchotikul
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

3.  A second-generation linkage map of the human genome.

Authors:  J Weissenbach; G Gyapay; C Dib; A Vignal; J Morissette; P Millasseau; G Vaysseix; M Lathrop
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

4.  Intron/exon structure of the human gene for the muscle isozyme of glycogen phosphorylase.

Authors:  J Burke; P Hwang; L Anderson; R Lebo; F Gorin; R Fletterick
Journal:  Proteins       Date:  1987

5.  McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases.

Authors:  C Bartram; R H Edwards; J Clague; R J Beynon
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

6.  Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease).

Authors:  S Tsujino; S Shanske; S DiMauro
Journal:  N Engl J Med       Date:  1993-07-22       Impact factor: 91.245

7.  A microsatellite-based index map of human chromosome 11.

Authors:  M Litt; P Kramer; X Y Hauge; J L Weber; Z Wang; P J Wilkie; M S Holt; S Mishra; H Donis-Keller; L Warnich
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

8.  Dinucleotide repeat polymorphism at the int-2 proto-oncogene locus (INT2).

Authors:  M H Polymeropoulos; H Xiao; D S Rath; C R Merril
Journal:  Nucleic Acids Res       Date:  1990-12-25       Impact factor: 16.971

9.  Three new mutations in patients with myophosphorylase deficiency (McArdle disease).

Authors:  S Tsujino; S Shanske; I Nonaka; Y Eto; J R Mendell; G M Fenichel; S DiMauro
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

10.  A mutation in CFTR produces different phenotypes depending on chromosomal background.

Authors:  S Kiesewetter; M Macek; C Davis; S M Curristin; C S Chu; C Graham; A E Shrimpton; S M Cashman; L C Tsui; J Mickle
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

View more
  2 in total

Review 1.  Molecular genetics of McArdle's disease.

Authors:  G Nogales-Gadea; J Arenas; A L Andreu
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 2.  McArdle disease: molecular genetic update.

Authors:  A L Andreu; G Nogales-Gadea; D Cassandrini; J Arenas; C Bruno
Journal:  Acta Myol       Date:  2007-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.